Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vildagliptin + Metformin Clear all
Completed Phase 3 Interventional

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

NCT00138515
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 78 Years
Enrollment
418 participants
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes

NCT00237237
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 77 Years
Enrollment
588 participants
Timeline
Started 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

NCT00099892
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes

NCT00382096
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin, Metformin, Vildagliptin + Metformin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
1,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

NCT00138567
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 78 Years
Enrollment
530 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

NCT00396227
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin, thiazolidinedione (TZD)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,665 participants
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)

NCT00728351
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin + metformin, metformin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
16
States / cities
Pine Bluff, Arkansas • Long Beach, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone

NCT00396357
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin, metformin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

NCT00468039
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin + metformin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 78 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

NCT00106340
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin, glimepiride, Metformin, Vildagliptin matching placebo, Glimepiride matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 73 Years
Enrollment
3,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes

NCT00351884
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin AM, vildagliptin pm, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 23, 2026, 6:23 AM EDT